SequelSEC

ANI PHARMACEUTICALS INC ANIP

Pharmaceutical Preparations · CIK 0001023024 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$978.38M
Fiscal year ended 2026-06-30
Operating income
$150.36M
Fiscal year ended 2026-06-30
Free cash flow
$172.99M
Fiscal year ended 2026-06-30

ANI PHARMACEUTICALS INC (ANIP) reported revenue of $978.38M and net income of $108.31M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ANI PHARMACEUTICALS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ANI PHARMACEUTICALS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$978.38M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$150.36M
Net income$108.31M
Research & development$49.91M
Weighted-average diluted sharesUnavailable
Pretax income$142.60M
Income tax expense$34.29M
Diluted EPS$4.63
Selling, general & administrative$324.76M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

ANI PHARMACEUTICALS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$360.21M
Total assets$1.49B
Current assets$825.43M
Total liabilities$896.90M
Current liabilities$283.66M
Total equity incl. NCI$597.21M
Temporary (mezzanine) equityUnavailable
Inventory$143.15M
Accounts receivable$274.47M
Goodwill$62.48M
Long-term debt$280.16M
Accounts payable$73.83M

Cash flow

ANI PHARMACEUTICALS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$189.47M
Capital expenditures$16.48M
Investing cash flow-$21.94M
Financing cash flow-$24.55M
Net change in cash$142.41M
Stock-based compensation$41.06M
Common dividends paid$344.00K
Common share repurchases$22.22M
Depreciation & amortization$85.80M

Derived

ANI PHARMACEUTICALS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$172.99M
Gross marginUnavailable
Operating margin15.4%
FCF margin17.7%
SBC / revenue4.2%
Current ratio2.91x
Revenue YoY growth30.9%
Net margin11.1%
R&D / revenue5.1%
CapEx / revenue1.7%
Long-term debt / equity0.47x
Effective tax rate24.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ANIP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.